Clinical trials recruiting in Arizona

Phase breakdown

Cities in Arizona

Conditions recruiting in Arizona

Recruiting trials in Arizona

• 4-aminopyridine Treatment for Nerve Injury
  NCT03701581 · Phase: Phase 2, Phase 3 · Ages: 45 Years to 75 Years · Sex: Male
• 52-week Open Label Safety-Tolerability Study
  NCT07369154 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
  NCT07332000 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male
• A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis Pain
  NCT07641517 · Phase: Phase 2 · Ages: 40 Years and older · Sex: All (male and female)
• A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
  NCT06925737 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
  NCT04370587 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
  NCT07060807 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
  NCT06966700 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
  NCT07218029 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
  NCT07351045 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
  NCT07351058 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
  NCT06892548 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
  NCT07070232 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Clinical Trial of Soluble Fiber for Asthma
  NCT06372249 · Phase: Phase 2 · Ages: 6 Years to 17 Years · Sex: All (male and female)
• A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
  NCT07170150 · Phase: Phase 3 · Ages: 50 Years to 90 Years · Sex: All (male and female)
• A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine
  NCT07018713 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine
  NCT07018700 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
  NCT07094516 · Phase: Phase 2 · Ages: 50 Years to 85 Years · Sex: All (male and female)
• A Culturally-relevant Micronutrient-dense Plant-rich (mNDPR) Dietary Intervention for Native Americans
  NCT04755062 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
  NCT06872125 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female)
• A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies
  NCT05753722 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
  NCT06692738 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
  NCT05211895 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
  NCT06405087 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female)
• A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
  NCT07674654 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
  NCT06747949 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Long-term Follow-up Study in Patients Who Received BEAM-101
  NCT07373639 · Phase: Not specified · Ages: 14 Years to 37 Years · Sex: All (male and female)
• A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
  NCT04641247 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
  NCT07185009 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female)
• A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
  NCT07483073 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain
  NCT05986292 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
  NCT06143956 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
  NCT07165028 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
  NCT07667803 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
  NCT05873686 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
  NCT07636785 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
  NCT06427941 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
  NCT05914116 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
  NCT06570798 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
  NCT06680830 · Phase: Phase 2 · Ages: 40 Years to 80 Years · Sex: All (male and female)
• A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
  NCT06568692 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
  NCT06695845 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
  NCT07115329 · Phase: Phase 2 · Ages: 18 Years to 64 Years · Sex: All (male and female)
• A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
  NCT07113522 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors
  NCT07656727 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
  NCT07599813 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
  NCT07690371 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female)
• A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
  NCT07285655 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
  NCT07011745 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female)
• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
  NCT07011732 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female)
• A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis
  NCT05862272 · Phase: Phase 3 · Ages: 18 Years to 50 Years · Sex: Female
• A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
  NCT06906562 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
  NCT06742723 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.
  NCT07619131 · Phase: Phase 3 · Ages: 18 Years to 130 Years · Sex: All (male and female)
• A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
  NCT07662135 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.
  NCT07222917 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
  NCT07221227 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
  NCT06996782 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
  NCT06672549 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female)
• A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
  NCT05519475 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
  NCT05489705 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
  NCT07196748 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female)
• A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
  NCT06112418 · Phase: Not applicable (e.g. observational or device study) · Ages: 55 Years and older · Sex: All (male and female)
• A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease
  NCT07214376 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 85 Years · Sex: All (male and female)
• A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
  NCT07172516 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female)
• A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
  NCT06775379 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female)
• A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
  NCT06664619 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female)
• A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
  NCT06581406 · Phase: Phase 2, Phase 3 · Ages: No age limits stated · Sex: All (male and female)
• A Registry for People With Lung Cancer
  NCT06424327 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
  NCT06979362 · Phase: Phase 2 · Ages: 40 Years to 84 Years · Sex: All (male and female)
• A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
  NCT07481630 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
  NCT06609226 · Phase: Phase 3 · Ages: 2 Years and older · Sex: All (male and female)
• A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
  NCT07564414 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
  NCT07567001 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A SMART Trial of Adaptive Exercises to Optimize Aerobic-Fitness Responses
  NCT05877196 · Phase: Not applicable (e.g. observational or device study) · Ages: 65 Years and older · Sex: All (male and female)
• A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
  NCT04729114 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male
• A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
  NCT06228326 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study Assessing Long-Term Safety and Effectiveness in Treatment Management of Atrial Fibrillation With VARIPULSE Catheter System
  NCT07227532 · Phase: Not applicable (e.g. observational or device study) · Ages: 22 Years and older · Sex: All (male and female)
• A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
  NCT07005128 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female)
• A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
  NCT06435429 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
  NCT06411249 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female)
• A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice
  NCT07556159 · Phase: Not specified · Ages: 6 Years and older · Sex: All (male and female)
• A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
  NCT06528314 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
  NCT06215716 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
  NCT06793215 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
  NCT06790693 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
  NCT06318169 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
  NCT06283966 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female)
• A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
  NCT06433752 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
  NCT04929223 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
  NCT05800665 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male
• A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
  NCT07567846 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male
• A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
  NCT05076175 · Phase: Phase 2, Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female)
• A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
  NCT05995964 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
  NCT06246916 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
  NCT06285643 · Phase: Phase 2 · Ages: 45 Years to 75 Years · Sex: All (male and female)
• A Study of AMDX-2011P in Participants With Alzheimer's Disease
  NCT06514001 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
  NCT04657068 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of AZD0120 in Autoimmune Diseases
  NCT07295847 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
  NCT07654374 · Phase: Phase 3 · Ages: 18 Years to 79 Years · Sex: All (male and female)

Showing 100 of 744 recruiting trials.

Common questions

How many clinical trials are recruiting in Arizona?

744 recruiting trials have at least one study site in Arizona.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.